Ozempic vs Trulicity

Ozempic (semaglutide) and Trulicity (dulaglutide) are both once-weekly injectable GLP-1 receptor agonists approved by the FDA for improving glycemic control in adults with type 2 diabetes. Both are well-established medications in the GLP-1 class, and both have demonstrated cardiovascular benefit in large outcomes trials. In the SUSTAIN 6 trial, semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk. Similarly, the REWIND trial demonstrated that dulaglutide reduced MACE in a broad population of adults with type 2 diabetes.

In head-to-head comparison, the SUSTAIN 7 trial evaluated semaglutide versus dulaglutide directly in adults with type 2 diabetes over 40 weeks. In that trial, semaglutide demonstrated superior A1C reduction and greater weight loss compared to dulaglutide at both low and high dose pairings. According to the broader clinical trial programs, Ozempic has been associated with approximately 1.8% A1C reduction and up to 14.9% body weight reduction at maximum doses, while Trulicity has shown approximately 1.5% A1C reduction and around 3.1% body weight reduction. These figures come from different trials with varying populations and durations, so they should be interpreted with caution. The SUSTAIN 7 head-to-head data provides a more reliable direct comparison.

Both medications share a similar gastrointestinal side-effect profile, including nausea, vomiting, diarrhea, and abdominal pain, which tend to be most pronounced during dose escalation. Both are self-administered via prefilled injection pens. Trulicity has been available since 2014, giving it a longer track record and broader familiarity among prescribers, and it may be available at a lower cost or with different formulary positioning depending on the patient's insurance plan. Ozempic, approved in 2017, is generally considered more effective for both glycemic control and weight reduction based on head-to-head trial evidence. The choice between these two medications should be made in consultation with a healthcare provider, taking into account individual clinical needs, tolerability, cost, and insurance coverage.